Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer

0 118

Cited 0 times in

DC Field	Value	Language
dc.date.accessioned	2023-06-02T00:53:58Z	-
dc.date.available	2023-06-02T00:53:58Z	-
dc.date.issued	2022-05	-
dc.identifier.issn	0923-7534	-
dc.identifier.uri	https://ir.ymlib.yonsei.ac.kr/handle/22282913/194506	-
dc.description.statementOfResponsibility	restriction	-
dc.language	English	-
dc.publisher	Oxford University Press	-
dc.relation.isPartOf	ANNALS OF ONCOLOGY	-
dc.rights	CC BY-NC-ND 2.0 KR	-
dc.title	Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer	-
dc.type	Article	-
dc.contributor.college	College of Medicine (의과대학)	-
dc.contributor.department	Dept. of Internal Medicine (내과학교실)	-
dc.contributor.googleauthor	H.K. Ahn	-
dc.contributor.googleauthor	K. Park	-
dc.contributor.googleauthor	S.H. Sim	-
dc.contributor.googleauthor	K.J. Suh	-
dc.contributor.googleauthor	M.H. Kim	-
dc.contributor.googleauthor	W-Y. Park	-
dc.contributor.googleauthor	Y-L. Choi	-
dc.contributor.googleauthor	S-A. Im	-
dc.contributor.googleauthor	K.H. Jung	-
dc.contributor.googleauthor	Y.H. Park	-
dc.identifier.doi	10.1016/j.annonc.2022.03.020	-
dc.relation.journalcode	J00171	-
dc.identifier.eissn	1569-8041	-
dc.identifier.url	https://www.sciencedirect.com/science/article/pii/S0923753422003994	-
dc.citation.volume	33	-
dc.citation.number	Suppl 3	-
dc.citation.startPage	S125	-
dc.citation.endPage	S126	-
dc.identifier.bibliographicCitation	ANNALS OF ONCOLOGY, Vol.33(Suppl 3) : S125-S126, 2022-05	-

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Show simple item record Find it @ YMLIB

YUHSpace: Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer